This study breaks new ground in two vital respects.
“First, we conclude, in addition to countering SARS-CoV-2, Xlear is likely effective in preventing the spread of future H1N1 viruses, including the emerging SARS-CoV-2 variants, along with other viral epidemics. Given the more transmissible variants we now face, this is critical now,” said Professor Mark Cannon, Feinberg School of Medicine, Northwestern University, in a press release issued on January 26, 2021.
“Second, using electron microscopy, we have visual evidence showing that xylitol and GSE counter the virus. The grapefruit seed extract (GSE) kills the virus, while the xylitol prevents the virus from attaching to the cell walls.”
“The image shows SARS-CoV-2 viruses outside the cell and never attached, thereby preventing infection,” added Dr. Cannon.
The study postulates that xylitol acts as a decoy target for SARS-CoV-2, preventing virus attachment to the cell wall’s core protein.
The collaborative study concludes: “Because there are no risk factors in using the X/GSE combination therapy [and] Xlear allows for comfortable long term mask-wearing, adoption of this preventive anti-viral therapy should be encouraged.”